Big boys coming to play ball!!!!!!!!
Shorts slap yourself, your a joke if you think they're going Into bankruptcy.
Which tells you are value should b between 9 and 5 Billion.
Announced CELG acquisition in July for $232 P/S; 23 Million diluted shares; 7.2 Billion dollar acq.
They were saying verbatim what ARNA is saying now!
San Diego Tribne:
Pharmaceutical giant Eli Lilly will greatly expand its research center in La Jolla so it can strengthen its already deep collaborations with UC San Diego and the region’s biomedical institutes.
The Indianapolis-based company said its local workforce will grow to 330 from 200, mostly through the addition of scientists who work on autoimmune disorders and other afflictions.
It plans to nearly double its research space to 300,000 square feet by taking over a building that’s being vacated by Qualcomm.
The moves are part of a nationwide research boom by Eli Lilly, whose history includes helping to purify insulin to treat diabetes, mass producing the Salk polio vaccine, introducing the first genetically engineered human insulin and developing medications to fight cancer, depression and osteoporosis. The conglomerate also identified and developed Prozac, a groundbreaking antidepressant.
“We’ve always known that San Diego was a hub for science, but actually having a presence here really brought it to life for us,” said Thomas Bumol, the company’s senior vice president for biotechnology and immunology. “We’ve seen significant advances at (the local biomedical institutes), at UCSD. This has become quite an exciting center for us for collaboration.”
Two years ago, Eli Lilly awarded UC San Diego a $76.6 million grant to help the company carry out clinical trials of a drug aimed at treating Alzheimer’s disease.
In May, the company announced that it will partner with the Sanford Burnham Prebys Medical Discovery Institute in La Jolla to seek out treatments for a variety of autoimmune disorders, including lupus and inflammatory bowel disease.
Those alliances build on Eli Lilly’s roughly 35-year-history in San Diego, which began with the purchase of Hybritech, the county’s first biotech company.
Hybritech faded afterward, and Eli Lilly sold the business several years later. Nevertheless, the initial Hybritech sale established the San Diego model of discovering important new products, building growth-minded companies around them and selling off those businesses for huge profits. Much of the profits are then invested in forming more start-ups.
“Eli Lilly was the pioneer large pharma company in San Diego when it acquired Hybritech ... and has continually demonstrated its confidence in the region over the years, as it has continually increased its research presence through further acquisition of our early stage companies, venture investment and the construction of the facility at Campus Point (Drive) several years ago,” said Joseph Panetta, executive director of the San Diego-based trade group Biocom.
Bumol said his corporation’s interest in this region has risen in recent years as Sanford Burnham and UC San Diego have invested heavily in translational medicine, the burgeoning, national movement of efforts to more quickly transform basic lab discoveries into drugs and other therapies.
Someone must be getting very anxious!
It does have me a little worried!
Do your due diligence folks
2013 68 Million shares short to now 17 million short and the price has decreased with the short interest decrease. These does not follow the laws of supply and demand!
Long ARNA and hold 45k shares
Sentiment: Strong Buy
At the most 41!
I wonder what would happen to the Short interest?
So they'll tell you the pps is dropping which it has the the cost of borrowing over the last few years has cost Them greatly, make no mistake.
Brazil and Mexico approvals expected this year. XR expected this year.